Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

Core Insights - Biomerica, Inc. announced real-world results demonstrating the effectiveness of its inFoods IBS product, which includes a new real-time patient feedback system to enhance symptom tracking and improve patient outcomes [1][2] Group 1: Product Effectiveness - The initial analysis from over 360 patients showed an average reduction of 48.5% in gastrointestinal pain and 49.8% in bloating over an 8-week period [6][7] - The real-world outcomes align with and in some cases exceed results from prior randomized clinical trials conducted at leading U.S. medical centers [1] Group 2: Real-Time Feedback System - Biomerica's HIPAA-compliant platform provides physicians with visibility into patient-reported outcomes, allowing for data-informed decisions and adjustments to treatment plans [2] - The real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomes [6] Group 3: Market Need and Impact - IBS affects an estimated 10% to 15% of adults in the U.S., leading to decreased quality of life and reliance on medications with adverse side effects [4] - The inFoods IBS product offers a novel diagnostic-guided solution that identifies individual food triggers, enabling targeted dietary changes without pharmaceuticals [4][5] Group 4: Clinical Validation - Peer-reviewed results published in Gastroenterology indicated that patients on an inFoods IBS-guided diet experienced significantly more abdominal pain relief compared to those on a placebo diet (59.6% vs. 42.1%, p-value=0.02) [3]